SEBI Reg. Investment Advisor

Download App

Help Center Subscribe

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 76741.82
238.22 (0.31%)

Filter

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
31	Onesource Specialty Pharma Ltd.	Q V PT	18,467 Small Cap	1,625.60 (0.92%)	878.87	3.13	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
32	Aarti Pharmalabs Ltd.	Q V+ PT	6,231 Small Cap	702.05 (2.18%)	36.13	3.21	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
33	Dr. Agarwals Health Care Ltd.	Q V PT	15,112 Small Cap	485 (1.73%)	115.43	7.59	26.38	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
34	Sun Pharma Advanced Research Company Ltd.	Q V+ PT	8,775 Small Cap	277.40 (2.59%)	5.8	6.75	-1.35	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
35	Panacea Biotec Ltd.	Q V+ PT	3,226 Small Cap	555.45 (5.46%)	N/A	11.93	-8.75	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
36	Nephrocare Health Services Ltd.	Q V+ PT	6,435 Small Cap	631.60 (-1.51%)	N/A	6.53	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
37	Fischer Medical Ventures Ltd.	Q V PT	2,424 Small Cap	38.10 (2.89%)	N/A	7.99	96.10	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
38	Gujarat Kidney And Super Speciality Ltd.	Q V+ PT	1,013 Small Cap	130.85 (1.87%)	104.2	4.19	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
39	Blue Jet Healthcare Ltd.	Q V PT	9,746 Small Cap	574.80 (2.30%)	40.23	7.33	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
40	Healthcare Global Enterprises Ltd.	Q V+ PT	9,455 Small Cap	651.85 (2.94%)	667.51	6.06	13.15	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
41	Lupin Ltd.	Q V PT	1,12,363 Mid Cap	2,502.90 (1.85%)	21.46	5.1	8.11	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
42	Fabtech Technologies Ltd.	Q V PT	697 Small Cap	160.40 (2.26%)	29.4	1.83	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
43	Sanofi Consumer Healthcare India Ltd.	Q V+ PT	10,452 Small Cap	4,508.40 (-0.66%)	40.26	22.98	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
44	Aster DM Quality Care Ltd.	Q V+ PT	40,403 Mid Cap	806.85 (3.47%)	107.7	9.14	-13.71	0.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
45	Hester Biosciences Ltd.	Q V PT	1,774 Small Cap	2,094.20 (0.44%)	34.19	4.63	6.98	0.80	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
46	Fermenta Biotech Ltd.	Q V PT	1,076 Small Cap	401.10 (9.74%)	18.36	2.79	7.46	0.93	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
47	Syngene International Ltd.	Q V+ PT	16,514 Small Cap	415.50 (1.56%)	55.01	3.6	9.45	1.26	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
48	FDC Ltd.	Q V PT	6,849 Small Cap	431.85 (2.65%)	24.59	2.82	9.23	1.32	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
49	Metropolis Healthcare Ltd.	Q V PT	11,413 Small Cap	560.10 (1.75%)	61.12	7.67	9.22	2.10	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
50	Bajaj Healthcare Ltd.	Q V PT	1,123 Small Cap	349.85 (4.84%)	55.27	2.21	5.76	2.91	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
51	Eris Lifesciences Ltd.	Q V PT	19,594 Small Cap	1,431.40 (1.24%)	32.02	5.08	21.92	3.58	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
52	Aarti Drugs Ltd.	Q V+ PT	3,537 Small Cap	395.75 (2.12%)	18.53	2.33	5.74	4.42	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
53	Bliss GVS Pharma Ltd.	Q V+ PT	5,409 Small Cap	523.70 (2.86%)	57.44	4.87	9.41	4.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
54	Ipca Laboratories Ltd.	Q V+ PT	44,676 Mid Cap	1,771.75 (0.61%)	39.69	5.63	8.87	4.68	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
55	Alivus Life Sciences Ltd.	Q V PT	13,832 Small Cap	1,142.45 (1.38%)	24.84	4.21	9.20	6.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
56	Gland Pharma Ltd.	Q V PT	41,120 Small Cap	2,469.05 (-0.95%)	31.34	3.77	9.35	7.37	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
57	Sigachi Industries Ltd.	Q V+ PT	831 Small Cap	22.18 (1.98%)	N/A	1.78	24.05	7.49	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
58	Themis Medicare Ltd.	Q V PT	1,032 Small Cap	116.65 (4.11%)	N/A	4	15.00	7.68	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
59	Thyrocare Technologies Ltd.	Q V+ PT	8,312 Small Cap	534.50 (2.35%)	52.06	14.7	10.88	8.62	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
60	Pfizer Ltd.	Q V PT	20,709 Small Cap	4,600.50 (1.63%)	29.13	5.01	2.39	8.89	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Unichem Laboratories	651.30	13.93%
Fermenta Biotech	401.10	9.74%
Suven Life Sciences	346.20	9.09%
RPG Life Sciences	2,658	8.13%
KMC Speciality Hosp.	136.25	7.58%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Dr. Reddys Labs.	1,269.80	-5.85%
Shree Ganesh Remed.	677.30	-2.03%
Nephrocare Health	631.60	-1.51%
Gland Pharma	2,469.05	-0.95%
Tarsons Products	288.20	-0.83%

News about Top Pharma Companies in India

Jul, 2026

HealthCare Global Enterprises submits scrutinizer’s report and voting results

HealthCare Global Enterprises has informed that, pursuant to provisions of Section 110 of the Companies Act, 2013, read with Rule 22 of the Companies (Management and Administration) Rules, 2014, Regulation 44(3) of SEBI Listing Regulations, and further to its intimation to Stock Exchanges on June 08, 2026, the approval of members of the Company was sought by remote e-voting process in respect of the resolutions set out in the Postal Ballot Notice dated June 08, 2026. In this regard, it enclosed the following: (i) Voting Results in compliance with Regulation 44(3) of SEBI Listing Regulations; and (ii) Consolidated Report of the Scrutinizer dated July 09, 2026, issued by, V Sreedharan, Senior Partner, V Sreedharan and Associates, Company Secretaries, on the remote e-voting conducted through the Postal Ballot process, pursuant to the provisions of Section 110 of the Companies Act, 2013 read with Rule 22 of the Companies (Management and Administration) Rules, 2014. Detailed information in this regard in accordance with Regulation 30 read with SEBI Circulars SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, and HO/49/14/14(7)2025- CFDPOD2/I/3762/2026 dated January 30, 2026, is annexed as Annexure-A. The above information is also available on the website of the Company and can be accessed at: https://www.hcgoncology.com/.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Sigachi Industries informs about non-applicability of certificate

In accordance with Regulation 74(5) of the SEBI (Depositories & Participants) Regulations, 2018 for the quarter ended June 30, 2026, Sigachi Industries has confirmed that the said Regulation is not applicable to the Company. The letter dated July 4, 2026 received from Bigshare Services (RTA) confirming the same is enclosed.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Hester Biosciences informs about corrigendum to AGM notice

Pursuant to applicable Regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Hester Biosciences has informed that it enclosed Corrigendum to the Notice for the Annual General Meeting scheduled to be held on Tuesday, 21 July 2026 at 10:30 am (IST) through Video Conference / Other Audio-Visual Means. Post-dispatch of the notice, it has come to the attention of the Company that due to an inadvertent typographical/ clerical error, one of the remuneration terms appearing in the Explanatory Statement to the resolution set out at Item No. 6 of the AGM Notice, relating to the re-appointment of the Executive Director of the Company, was incorrectly mentioned on page no. 17 of the AGM Notice. Accordingly, the company has informed that the gross salary shall be read as INR 10 lakh per month instead of INR 8.40 lakh per month, as mentioned in the Explanatory Statement. The said correction is only to rectify the inadvertent typographical / clerical error and is in line with the remuneration terms approved by the Board of Directors while considering the re-appointment of the Executive Director. This Corrigendum shall form an integral part of and should be read in conjunction with the Notice of the 39th Annual General Meeting. In view of the aforesaid, the inadvertent mistake is now rectified and the notice with the updated explanatory statement is attached.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Aster DM Healthcare informs about disclosure

Aster DM Healthcare has informed that the exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for BCP Asia II Topco IV.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Blue Jet Healthcare informs about resignation of statutory auditors

Blue Jet Healthcare has informed that the Board of Directors of Blue Jet Healthcare at its meeting held on May 25, 2026, has approved the audited standalone financial statements of the Company for the financial year ended March 31, 2026, together with the notes and schedules thereto and the audit report thereon, including the comparative figures for the financial year ended March 31, 2025, prepared in accordance with the applicable provisions of the Companies Act, 2013 and the applicable accounting standards. A copy of the audited standalone financial statements together with the notes and schedules thereto along with the audit report thereon is enclosed. The audited standalone financial statements of the Company for the financial year ended March 31, 2026, together with the notes and schedules thereto and the audit report thereon, are subject to adoption by the shareholders of the Company at the ensuing Annual General Meeting. The above intimation will also be available on the website of the Company, www.bluejethealthcare.com.

The above information is a part of company's filings submitted to BSE.

Jul, 2026

Sun Pharma Advanced Research Company informs about confirmation certificate

Sun Pharma Advanced Research Company has informed that it enclosed the Confirmation Certificate dated July 01, 2026, received from the Company’s Registrar and Share Transfer Agent, MUFG Intime (India) for the quarter ended June 30, 2026.

The above information is a part of company’s filings submitted to BSE.

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Nectar Lifesciences Ltd.	217 Crore
2	Health X Platform Ltd.	999 Crore
3	Indoco Remedies Ltd.	2,291 Crore
4	Unichem Laboratories Ltd.	4,025 Crore
5	Solara Active Pharma Sciences Ltd.	2,700 Crore
6	Suraksha Diagnostic Ltd.	1,372 Crore
7	Jubilant Pharmova Ltd.	15,465 Crore
8	Dishman Carbogen Amcis Ltd.	2,999 Crore
9	Fortis Healthcare Ltd.	71,238 Crore
10	Viyash Scientific Ltd.	11,839 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	26,763	55,743	35.92	11.68	24.53	35.71
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,897	1,64,737	76.15	19.64	39.95	29.04
Ajanta Pharma Ltd. (M)	Very Good	3,305	40,971	38.80	9.06	26.22	25.35
Lupin Ltd. (M)	Somewhat Good	2,503	1,12,363	21.07	5.01	12.19	20.83
Zydus Lifesciences Ltd. (M)	Very Good	1,160	1,14,613	22.74	4.41	13.91	20.74

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,503	79,403	89.38
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,441	39,082	49.49
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,897	1,64,737	45.97
Aurobindo Pharma Ltd. (M)	Very Good	1,587	89,581	38.69
Gland Pharma Ltd. (S)	Very Good	2,469	41,120	31.46
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,441	39,082	57.98	9.68	35.12	15.51
Mankind Pharma Ltd. (M)	Very Good	2,531	1,02,795	50.45	6.27	31.69	14.65
Ajanta Pharma Ltd. (M)	Very Good	3,305	40,971	38.80	9.06	26.22	13.54
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,270	1,12,573	26.83	2.98	14.97	12.09
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,897	1,64,737	76.15	19.64	39.95	11.80

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Zydus Lifesciences Ltd. (M)	Very Good	1,160	1,14,613	22.74	4.41	13.91	30.57
Abbott India Ltd. (M)	Very Good	26,763	55,743	35.92	11.68	24.53	18.78
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,270	1,12,573	26.83	2.98	14.97	15.75
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,939	4,52,982	39.46	5.42	22.61	14.41
Glenmark Pharmaceuticals Ltd. (M)	Very Good	2,265	62,757	46.08	5.97	12.24	14.41

You have 9 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

HealthCare Global Enterprises submits scrutinizer’s report and voting results

Sigachi Industries informs about non-applicability of certificate

Hester Biosciences informs about corrigendum to AGM notice

Aster DM Healthcare informs about disclosure

Blue Jet Healthcare informs about resignation of statutory auditors

Sun Pharma Advanced Research Company informs about confirmation certificate

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.